

## QLT PhotoTherapeutics Incorporated

[View the current QLT PhotoTherapeutics Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/8679-QLT+PhotoTherapeutics+Incorporated.html)

(<http://www.bioportfolio.com/biocorporate/8679-QLT+PhotoTherapeutics+Incorporated.html>)

### Contact Details:

**887 Great Northern Way  
Vancouver  
British Columbia  
V5T 4T5  
Canada**

Tel: 604 872 7881  
Fax: 604 875 0001  
Email:

QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies to treat cancer, eye diseases and immune disorders. Combining expertise in ophthalmology, oncology and photodynamic therapy, QLT has commercialized two products to date, including Visudyne® therapy which is the most successfully launched ophthalmology product ever.

### Recent Publications by QLT PhotoTherapeutics Incorporated:



- [IL-10 contributes to the inhibition of contact hypersensitivity in mice treated with photodynamic therapy.](#)  
*We have explored the effect of photodynamic therapy (PDT) with verteporfin...*25th March, 2000  
QLT PhotoTherapeutics- J Immunol. 2000 Mar 1;164(5):2457-62.

### BioNews Results for QLT PhotoTherapeutics Incorporated



- [Drug Patent Expirations in October 2008](#)  
*BioPortfolio: Oct 1 2008 10:27PM Matching: qlt*
- [Tekmira Pharmaceuticals Expands Executive Management Team](#)  
*Nanotechnology News: Sep 30 2008 1:59AM Matching: qlt*

- [Tekmira Pharmaceuticals Expands Executive Management Team](#)  
*TradingMarkets: Sep 29 2008 3:07PM Matching: qlt*
- [LifeSciences British Columbia](#)  
*BioSpace: Sep 27 2008 7:25AM Matching: qlt*
- [Michael P. Smith Promoted to CFO at Memory Pha](#)  
*Citybizlist: Sep 18 2008 6:24PM Matching: qlt*
- [Memory Pharmaceuticals Realigns Workforce to Support Development Programs](#)  
*PR Newswire: Sep 17 2008 11:26PM Matching: qlt*
- [QLT Announces Completion of the Redemption of 3% Convertible Senior Notes Due 2023](#)  
*Pharma Live: Sep 17 2008 5:38AM Matching: qlt*
- [Memory Pharmaceuticals Realigns Workforce to Support Development Programs](#)  
*Montana's News Station: Sep 17 2008 9:55PM Matching: qlt*
- [Memory Pharmaceuticals Realigns Workforce to Support Development Programs](#)  
*KSLA: Sep 17 2008 9:46PM Matching: qlt*
- [Memory Pharmaceuticals Realigns Workforce to Support Development Programs](#)  
*Cincinnati Business Journal: Sep 17 2008 8:36PM Matching: qlt*
- [Memory Pharmaceuticals Realigns Workforce to Support Development Programs](#)  
*Nashville Business Journal: Sep 17 2008 8:36PM Matching: qlt*
- [Memory Pharmaceuticals Realigns Workforce to Support Development Programs](#)  
*Atlanta Business Chronicle: Sep 17 2008 8:30PM Matching: qlt*
- [QLT Completes Cdn\\$65.5 million Real Estate Transaction](#)  
*Pharma Live: Sep 2 2008 1:02PM Matching: qlt*
- [QLT completes Cdn\\$65.5 million real estate transaction](#)  
*Therapeutics Daily: Sep 2 2008 12:26PM Matching: qlt*
- [QLT to licence its Atrigel technology to Reckitt Benckiser Pharmaceuticals](#)  
*Prince George Citizen: Aug 29 2008 4:26PM Matching: qlt*

#### QLT PhotoTherapeutics Incorporated Patents:



- 6107325- [Green porphyrins as immunomodulators](#)
- 5756541- [Vision through photodynamic therapy of the eye](#)
- 5834503- [Methods to treat arterial plaque](#)
- 5882328- [Method to prevent transplant rejection](#)
- 5883246- [Synthesis of polypyrrolic macrocycles from meso-substituted tripyrrane compounds](#)
- 5910510- [Vision through photodynamic therapy of the eye](#)
- 5945439- [Method for destroying or inhibiting growth of unwanted cells or tissues](#)
- 6008241- [Green porphyrins as immunomodulators](#)
- 6043237- [Use of photodynamic therapy for prevention of secondary cataracts](#)
- 6074666- [Liposome compositions of porphyrin photosensitizers](#)
- 6086558- [Balloon catheter for photodynamic therapy](#)
- 6096776- [Green porphyrins as immunomodulators](#)
- 5707608- [Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's relate service indepth.

The annual cost is \$495.00 for established organizations and \$295.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

